Bharat Serums and Vaccines Develops New Formulation of Cancer Drug
Bharat Serums and Vaccines, a provider of plasma, pharma and biotechnology products, has developed a novel formulation of docetaxel, which is free from surfactant Polysorbate-80.
This formulation could potentially be a breakthrough in avoiding the fluid retention or hypersensitivity and extravasation reactions which are associated with Taxotere.
Initial preclinical studies have shown a higher safety and a superior pharmacokinetic profile when compared to Taxotere. Efficacy in tumor bearing mice has also been established for the newly developed formulation, the company said.
Taxotere is a branded formulation of docetaxel and has limitations like hypersensitivity or allergic reactions due to the excipients used in the formulation.
Bharat Serums and Vaccines is in exploratory discussions with pharmaceutical companies for collaboration in commercializing the docetaxel novel formulation for various world wide markets.